Lv6
1750 积分 2024-11-20 加入
Abstract CT261: Phase II trial of nivolumab in combination with talazoparib in patients with unresectable or metastatic melanoma and mutations in BRCA or BRCA-ness
1个月前
已完结
Combination of CHK1 and CHK2 inhibitors exerts synergistic antitumor effects against neuroblastoma cells
2个月前
已完结
Radiopharmaceutical Therapy Meets Radiobiology: Implications for Trial Design and DNA Repair Inhibitor Combinations
2个月前
已关闭
Dual inhibition of PARP and ATR induces synthetic lethal vulnerability in prostate cancer with CDK12 deficiency
3个月前
已完结
Dual inhibition of PARP and ATR induces synthetic lethal vulnerability in prostate cancer with CDK12 deficiency
3个月前
已关闭
Pregnancy outcomes in patients with vitiligo: A nationwide population-based cohort study from Korea
3个月前
已完结
Integrating homologous recombination deficiency and replication stress: converging strategies unlocking new frontiers in precision oncology
3个月前
已完结
Comparative in vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation
3个月前
已完结
Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
3个月前
已完结
HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancer
3个月前
已关闭
皖公网安备34019202002308
